期刊文献+

小剂量利妥昔单抗治疗系统性红斑狼疮的临床观察 被引量:2

下载PDF
导出
摘要 目的:探讨小剂量利妥昔单抗治疗系统性红斑狼疮(SLE)的临床观察。方法:选取2010年2月∽2014年2月在我院患有系统性红斑狼疮的患者50例作为研究对象,采用小剂量的利妥昔单抗对这些患者进行治疗。对治疗前后英国狼疮评估小组和SLE疾病活动指数积分进行评估,比较治疗前,治疗2个月及治疗10个月的外周B细胞含量的变化。结果:通过治疗前后英国狼疮评估小组和SLE疾病活动指数积分的评估,治疗后患者情况明显好于治疗前,通过比较B细胞的清除率,发现小剂量的利妥昔单抗能够使B细胞的重建成功,统计学上有意义(p<0.05)。结论:治疗系统性红斑狼疮时使用小剂量利妥昔单抗有显著的效果,能够有效地清除B细胞并且重建,安全性较高,值得在临床上推广使用。
作者 丁艳杰
出处 《中国伤残医学》 2014年第23期129-130,共2页 Chinese Journal of Trauma and Disability Medicine
  • 相关文献

参考文献5

二级参考文献66

  • 1孙惠力,尹培达.利妥昔单抗治疗系统性红斑狼疮研究进展[J].中华风湿病学杂志,2006,10(6):369-371. 被引量:7
  • 2Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension [ J ~. Eur Respir J, 2003, 22 : 358 - 363.
  • 3Ulrich S, Taraseviciene-Stewart L, Huber LC,et al. Peripheral blood B lymphocytes derived from patients with idi- opathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study [ J]. Respiratory Research, 2008, 9:20.
  • 4Daley E, Emson C, Guignabert C, et al. Pulmonary arterial remodeling induced by a Th2 immune response [ J ]. J Exp Med, 2008, 205(2):361 -372.
  • 5Allanore Y, Borderie D, Meune C, et al. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers [J]. Ann Rheum Dis, 2005, 64:481 -483.
  • 6Damas JK, Otterdal K, Yndestad A, et al. Soluble CD40 ligand in pulmonary arterial hypertension: Possible pathogenic role of the interaction between platelets and endothelial cells [ J]. Circulation, 2004, 110:999 - 1005.
  • 7Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling [ J ]. Am J Respir Crit Care Med, 2007, 1175:1280 - 1289.
  • 8Ulrich S, Nicolls MR, Taraseviciene-Stewart L, et al. Increased regulatory and decreased CD8 + cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension [ J]. Respiration, 2008, 75:272- 280.
  • 9Liossis S, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells [ J ]. Clinical Immunology, 2008, 127:280 - 285.
  • 10Sfikakis PP, Souliotis VL, Fragiadaki KG, et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis [ J]. Clinical Immunology, 2007, 123 : 66 - 73.

共引文献32

同被引文献26

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部